Form 4: Outset Medical Director Karen Prange Receives RSU Grant

Outset Medical Director Karen Prange was granted 18,667 Restricted Stock Units, vesting quarterly over three years.

Summary

• Karen Prange, a Director at Outset Medical, Inc. (OM), acquired 18,667 shares of Common Stock through a Restricted Stock Unit (RSU) grant.
• The transaction date for this acquisition was January 9, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• These RSUs will vest quarterly over a period of three years, contingent upon Ms. Prange's continued service to the company through the applicable vesting dates.
• The acquisition price for these RSUs was $0.0, as they are grants.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a standard equity grant to a director, aligning their interests with the company's long-term performance and shareholder value. It does not indicate any immediate operational or financial changes, but rather a routine compensation event.

Positives

• The grant of Restricted Stock Units to a director aligns management and director interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over three years encourages continued service and commitment from the director.

Risks

• The RSUs are subject to a vesting schedule, meaning the director must maintain continued service for three years to fully realize the shares, posing a forfeiture risk if service ceases prematurely.

Future Outlook

The vesting schedule of the RSUs over three years indicates an expectation of continued service from Director Karen Prange, aligning her future compensation with the company's long-term performance.

Industry Context

This RSU grant is a standard form of equity compensation for directors in publicly traded companies, particularly in the medical technology sector, aiming to retain talent and align interests with long-term shareholder value.

Comparison to Industry Standards

• Equity grants, such as RSUs, are a common component of director compensation packages across the medical device and broader technology industries, comparable to practices at companies like Medtronic, Intuitive Surgical, or Stryker, which use similar mechanisms to incentivize leadership.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value, potentially leading to more focused governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The RSUs will vest quarterly over the next three years, subject to Karen Prange's continued service.

Key Dates

Keywords

Outset Medical, OM, Karen Prange, Restricted Stock Units, RSU grant, insider transaction, Form 4, director compensation, equity incentive, vesting